Search Results

Acasti Pharma Inc. announced that the Company will be participating in the BIO International Convention taking place at the San Diego Convention Center from June 3-6, 2024.

Acasti Pharma Inc. today announced financial results and business highlights for the year ended March 31, 2024.

Acasti Pharma Inc. announced that the Company’s pivotal Phase 3 STRIVE-ON safety trial has exceeded the 50% enrollment milestone.

Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector-specific duties “in the next month or so.”

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST) today announced financial and operational results for the fiscal year ended March 31, 2023.

Playing both sides of trade war, pharma companies are asking for certain compensations for scientific innovation and a smoother regulatory framework.

Trump could use the findings of the probe to impose certain trade restrictions on pharma products, including tariffs.

Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced financial results and business highlights for the quarter ended December 31, 2023.

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of rivalry that includes blockbuster drugs Keytruda, Humira and Eliquis.